Athersys Inc (ATHXQ)
OTCMKTS: ATHXQ · Delayed Price · USD
0.0044
0.00 (0.00%)
Apr 26, 2024, 3:58 PM EDT - Market closed
Athersys Revenue
Athersys had revenue of $145.00K in the twelve months ending June 30, 2023, down -98.65% year-over-year. Revenue in the quarter ending June 30, 2023 was $49.00K, a -97.88% decrease year-over-year. In the year 2022, Athersys had annual revenue of $5.33M, a decrease of -3.43%.
Revenue (ttm)
$145.00K
Revenue Growth
-98.65%
P/S Ratio
0.63
Revenue / Employee
$6,042
Employees
24
Market Cap
91.08K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 5.33M | -189.00K | -3.43% |
Dec 31, 2021 | 5.51M | 4.07M | 282.92% |
Dec 31, 2020 | 1.44M | -4.19M | -74.44% |
Dec 31, 2019 | 5.63M | -18.66M | -76.81% |
Dec 31, 2018 | 24.29M | 20.58M | 555.10% |
Dec 31, 2017 | 3.71M | -13.64M | -78.62% |
Dec 31, 2016 | 17.35M | 5.40M | 45.19% |
Dec 31, 2015 | 11.95M | 10.33M | 636.17% |
Dec 31, 2014 | 1.62M | -815.00K | -33.43% |
Dec 31, 2013 | 2.44M | -6.27M | -72.00% |
Dec 31, 2012 | 8.71M | -1.64M | -15.82% |
Dec 31, 2011 | 10.34M | 1.41M | 15.72% |
Dec 31, 2010 | 8.94M | 6.78M | 314.03% |
Dec 31, 2009 | 2.16M | -946.00K | -30.47% |
Dec 31, 2008 | 3.11M | -155.00K | -4.75% |
Dec 31, 2007 | 3.26M | -465.00K | -12.48% |
Dec 31, 2006 | 3.73M | 129.00K | 3.59% |
Dec 31, 2005 | 3.60M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 45.81B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
ATHXQ News
- 5 months ago - Athersys Reports Third Quarter 2023 Financial Results and Business Highlights - Business Wire
- 6 months ago - Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives - Business Wire
- 7 months ago - Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios - Business Wire
- 7 months ago - Athersys Licenses its Animal Health Assets to Ardent Animal Health - Business Wire
- 7 months ago - Athersys Director Jane Wasman Appointed Board Chair - Business Wire
- 8 months ago - Grant Awarded to Newcastle University to Research Athersys' MultiStem® in Machine Perfusion Prior to Kidney Transplantation - Business Wire
- 9 months ago - Athersys, Inc. Announces Pricing of $3.5 Million Public Offering - Business Wire
- 9 months ago - Athersys Reports Second Quarter 2023 Financial Results and Business Highlights - Business Wire